Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 14, 2014 - Issue 1
Submit an article Journal homepage
332
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy

Peter J McKennaFIDMAG, Germanes Hospitalàries, and CIBERSAM, C/. Dr. Antoni Pujadas 38, 08830 Sant Boi de Llobregat, Barcelona, SpainCorrespondence[email protected]
&
Ann M MortimerThe Eleanor Centre, 21 Eleanor Street, GRIMSBY, North East Lincolnshire, DN32 9EA, UK
Pages 67-73 | Published online: 02 Dec 2013

References

  • Brenner HD, Dencker SJ, Goldstein MJ et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 16, 551–561 (1990).
  • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45, 789–796 (1988).
  • Kuipers E, Garety P, Fowler D et al. London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase. Br. J. Psychiatry. 171, 319–327 (1997).
  • NICE. Schizophrenia: Full National Clinical Guideline On Core Interventions In Primary And Secondary Care. Gaskell and the British Psychological Society, London (2003).
  • NICE. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). National Institute of Clinical Excellence, London, UK (2009).
  • Rathod S, Phiri P, Kingdon D. Cognitive behavioral therapy for schizophrenia. Psychiat. Clin. North America 33, 527–536 (2010).
  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41 (2009).
  • Kendall T. The rise and fall of the atypical antipsychotics. Br. J. Psychiatry. 199, 266–268 (2011).
  • Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321, 1371–1376 (2000).
  • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60, 553–564 (2003).
  • Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann. Int. Med. 157, 498–511 (2012).
  • Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).
  • Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63, 1079–1087 (2006).
  • Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? Am. J. Psychiatry 168, 770–775 (2011).
  • Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol. Med. 39, 1591–1602 (2009).
  • Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int. J. Clin Pract. 63, 1237–1248 (2009).
  • Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 24, 65–84 (2010).
  • Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J. Clin. Psychiatry 73, 1533–1540 (2012).
  • Sanford M. Lurasidone : in the treatment of schizophrenia. CNS Drugs 27, 67–80 (2013).
  • Schulze M, Siol O, Robaa D et al. Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates – characterization by in vivo experiments. Arzneimittle Forschung Drug Res. 6, 252–260 (2012).
  • Agai-Csongor E, Domany G, Nogradi K et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg. Med. Chem. Lett. 22, 3437–3440 (2012).
  • Gao M, Chu HY, Jin GZ, Zhang ZJ, Wu J, Zhen XC. l-Stepholidine-induced excitation of dopamine neurons in rat ventral tegmental area is associated with its 5-HT(1A) receptor partial agonistic activity. Synapse 65, 379–387 (2011).
  • Javitt DC. Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr. Bull. 38, 911–913 (2012).
  • Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72, 225–234 (2005).
  • Buchanan RW, Javitt DC, Marder SR et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593–1602 (2007).
  • Lieberman JA, Papadakis K, Csernansky J et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34, 1322–1329 (2009).
  • Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25, 859–885 (2011).
  • Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13, 1102–1107 (2007).
  • Kinon BJ, Zhang L, Millen BA et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 31, 349–355 (2011).
  • Olszewski RT, Janczura KJ, Ball SR et al. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Translat. Psychiatry 2, e145 (2012).
  • Alberati D, Moreau JL, Lengyel J et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62, 1152–1161 (2012).
  • Umbricht D. Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropharmacology 35, S320–S321 (2010).
  • Stone J. Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther. Adv. Psychopharmacol. 1, 5–18 (2011).
  • Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacology. 26, 1185–1193 (2012).
  • Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 12, 232–246 (2007).
  • Meltzer HY. EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. Neuropsychopharmacology 36, S170–S171 (2011).
  • Oliveros A, Heckman MG, Del Pilar Corena-McLeod M, Williams K, Boules M, Richelson E. Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine, clozapine and NT69L. J. Exp. Biology 213, 4232–2439 (2010).
  • Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World. J. Biol. Psychiatry 11, 208–219 (2010).
  • Leweke FM, Piomelli D, Pahlisch F et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translat. Psychiatry 2, e94 (2012).
  • Sensky T, Turkington D, Kingdon D et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch. Gen. Psychiatry 57, 165–172 (2000).
  • Lewis S, Tarrier N, Haddock G et al. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br. J. Psychiatry ( Suppl. 43), s91–s97 (2002).
  • Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. Br. J. Psychiatry 180, 523–527 (2002).
  • Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E. Cognitive--behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br. J. Psychiatry 192, 412–423 (2008).
  • van der Gaag M, Stant AD, Wolters KJ, Buskens E, Wiersma D. Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis. Br. J. Psychiatry 198( Suppl. 1), 59–65, (2011).
  • Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 34, 523–537 (2008).
  • Gumley A, O’Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. Psychol. Med. 33, 419–431 (2003).
  • Gleeson JF, Cotton SM, Alvarez-Jimenez M et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J. Clin. Psychiatry 70, 477–486 (2009).
  • Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch. Gen. Psychiatry (2011).
  • Aggarwal M, Basu D. Cognitive therapy in patients with schizophrenia. JAMA Psychiatry 70, 543–544 (2013).
  • Klingberg S, Wolwer W, Engel C et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr. Bull. 37( Suppl. 2), S98–S110 (2011).
  • Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323, 42–46 (2001).
  • Chambless DL, Hollon SD. Defining empirically supported therapies. J. Consult. Clin. Psychol. 66, 7–18 (1998).
  • Jensen PS, Weersing R, Hoagwood KE, Goldman E. What is the evidence for evidence-based treatments? A hard look at our soft underbelly. Ment. Health Serv. Res. 7, 53–74 (2005).
  • Kirsch I. Placebo psychotherapy: synonym or oxymoron? J. Clin. Psychol. 61, 791–803 (2005).
  • Bentall R. Doctoring the Mind: Why Psychiatric Treatments Fail. Allen Lane, NY, USA (2009).
  • Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Sys. Rev. 4, CD008712 (2012.)

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.